Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 3, 2009, Pages 262-272

  Fu, Qiang ^a   Sun, Jin ^a   Zhang, Wenping ^a   Sui, Xiaofan ^a   Yan, Zhongtian ^a   He, Zhonggui ^a  

^a School of Pharmacy   (China)

Author keywords

Albumin; Anti cancer drug; Nab technology; Paclitaxel

Indexed keywords

ALBUMIN; BEVACIZUMAB; CARBOPLATIN; GEMCITABINE; PACLITAXEL;

ANEMIA; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CLINICAL TRIAL; DOSE KIDNEY FUNCTION RELATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG FORMULATION; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; DRUG SAFETY; DRUG STABILITY; DRUG TARGETING; DRUG TOLERABILITY; DYSPNEA; EYE TOXICITY; FATIGUE; FEBRILE NEUTROPENIA; HEAD AND NECK CANCER; HUMAN; HYDROPHOBICITY; HYPERTENSION; KERATOPATHY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NANOPHARMACEUTICS; NEUROPATHY; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PARTICLE SIZE; PATENT; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROSTATE CARCINOMA; REVIEW; SENSORY NEUROPATHY; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TISSUE DISTRIBUTION; TONGUE CANCER;

ALBUMINS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PACLITAXEL;

EID: 70350776969     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209789206869     Document Type: Review

References (125)

1. http://www.who.int/mediacentre/factsheets/fs297/en/index.html
2. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 2000; 44: 235-249.
3. Bristol-Myers Squibb Co. Taxol (paclitaxel) Injection prescribing information. Princeton: New Jersey 2007.
4. Aventis Pharm Ltd. Taxotere (docetaxel) Injection Concentrate: Package Insert. Bridgewater; NJ. May 2004.
5. Desai, N. P., Tao, C., Yang, A., Louie, L., Yao, Z., Soon-Shiong, P., Magdassi, S.: US20046749868 (2004).
6. Desai, N. P., Soon-Shiong, P.: US20046753006 (2004).
7. Desai, N. P., Soon-Shiong, P.: US20036537579 (2003).
8. Desai, N. P., Soon-Shiong, P.: US20036506405 (2003).
9. Desai, N. P., Tao, C., Yang, A., Louie, L., Zheng, T., Yao, Z., Soon-Shiong, P., Magdassi, S.: US5916596 (1999).
10. Gupta RB, Kompella UB. Drugs and the pharmaceutical sciences: Nanoparticle technology for drug delivery. New York: Taylor & Francis Group 2006; 98-101.
11. Desai NP. Nab technology: A drug delivery platform utilising endothelial gp60 receptor-based transport and tumour-derived SPARC for targeting. Drug Deliv Report Winter 2007-2008, 37-41.
12. Desai, N. P., Soon-Shiong, P., De, T.: US20080063724A1 (2008).
13. John TA, Vogel SM, Tiruppathi C, Malik AB, Minshall RD. Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer. Am J Physiol Lung Cell Mol Physiol 2003; 284: 187-196.
14. Minshall RD, Sessa WC, Stan RV, Anderson RGW, Malik AB. Caveolin regulation of endothelial function. Am J Physiol Lung Cell Mol Physiol 2003; 285: L1179-1183.
15. Tiruppathi C, Song W, Bergenfeldt M, Sass P, Malik AB. Gp60 activation mediates albumin transcytosis in endothelial cells by tyrosine kinase-dependent pathway. J Biol Chem 1997; 272: 25968-25975.
16. Schnitzer JE. gp60 is an albumin-binding glycoprotein expressed by continuous endothelium involved in albumin transcytosis. Am J Physiol 1992; 262: H246-254.
17. Schilling U, Friedrich EA, Sinn H, et al. Design of compounds having enhanced tumour uptake, using serum albumin as a carrier: Part II. in vivo Studies. Int J Rad Appl Instrum B 1992; 19: 685-695.
18. Schnitzer JE, Oh P. Antibodies to SPARC inhibit albumin binding to SPARC, gp60, and microvascular endothelium. Am J Physiol 1992; 263: H1872-879.
19. Tiruppathi C, Finnegan A, Malik AB. Isolation and characterization of a cell surface albumin binding protein from vascular endothelial cells. Proc Natl Acad Sci USA 1996; 93: 250-254.
20. Desai NP, Trieu V, Yao Z, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of Cremophor-free, albumin-bound paclitaxel, ABI-007, compared with Cremophor-based paclitaxel. Clin Cancer Res 2006; 12: 1317-1324.
21. Vogel SM, Minshall RD, Pilipovic M, Tiruppathi C, Malik AB. Albumin update and transcytosis in endothelial cells in vivo induced by albumin-binding protein. Am J Physiol Lung Cell Mol Physiol 2001; 281: L1512-1522.
22. Desai NP, Trieu V, Yao R, et al. Increased transport of nanoparticle albumin-bound paclitaxel (ABI-007) by endothelial gp60-mediated caveolar transcytosis: A pathway inhibited by Taxol. 16th Annual Meeting of the European Organisation for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research. Geneva, Switzerland 2004.
23. Porter PL, Sage EH, Lane TF, Funk SE, Gown AM. Distribution of SPARC in normal and neoplastic human tissue. J Histochem Cytochem 1995; 43: 791-800.
24. Kim YW, Park YK, Lee J, Ko SW, Yang MH. Expression of osteopontin and osteonectin in breast cancer. J Korean Med Sci 1998; 13: 652-657.
25. Thomas R, True LD, Bassuk JA, Lange PH, Vessella RL. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000; 6: 1140-1149.
26. Brown TJ, Shaw PA, Karp X, et al. Activation of SPARC expression in reactive stroma associated with human epithelial ovarian cancer. Gynecol Oncol 1999; 75: 25-33.
27. Paley PJ, Goff BA, Gown AM, Greer BE, Sage EH. Alterations in SPARC and VEGF immunoreactivity in epithelial ovarian cancer. Gynecol Oncol 2000; 78: 336-341.
28. Ledda F, Bravo AI, Adris S, et al. The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. J Invest Dermatol 1997; 108: 210-214.
29. Massi D, Franchi A, Borgognoni L, Reali UM, Santucci M. Osteonectin expression correlates with clinical outcome in thin cutaneous malignant melanomas. Hum Pathol 1999; 30: 339-344.
30. Yamanaka M, Kanda K, Li NC, et al. Analysis of the gene expression of SPARC and its prognostic value for bladder cancer. J Urol 2001; 166: 2495-2499.
31. Yamashita K, Upadhay S, Mimori K, Inoue H, Mori M. Clinical significance of secreted protein acidic and rich in cysteine in esophageal carcinoma and its relation to carcinoma progression. Cancer 2003; 97: 2412-2419.
32. Rempel SA, Ge S, Gutierrez JA. SPARC: A potential diagnostic marker of invasive meningiomas. Clin Cancer Res 1999; 5: 237-241.
33. Trieu V, Damascelli B, Soon-Shiong P, Desai NP. SPARC expression in head and neck cancer correlates with tumor response to nanoparticles albumin-bound paclitaxel (nab-paclitaxel, ABI-007, Abraxane). 97th American Association of Cancer Research Annual Meeting, Washington, DC, USA 2006.
34. Desai NP, Trieu V, Yao R, et al. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs Taxol. 27th Annual San Antonio Breast Cancer Symposium, San Antonio, USA 2004.
35. Fang J, Sawa T, Maeda H. Factors and mechanism of "EPR" effect and the enhanced antitumor effects of macromolecular drugs including SMANCS. Adv Exp Med Biol 2003; 519: 29-49.
36. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumor itropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res 1986; 46: 6387-6392.
37. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: A review. J Control Release 2000; 65: 271-284.
38. Brunton L, Lazo J, Parker K. In: Goodman & Gilman's, Eds. The pharmacological basis of therapeutics 9th ed. McGraw-Hill Professional York 1996.
39. Fehske KJ, Müller WE, Wollert U. The location of drug binding sites in human serum albumin. Biochem Pharmacol 1981; 30(7): 687-692.
40. Vorum H. Reversible ligand binding to human serum albumin - Theoretical and clinical aspects. Dan Med Bull 1999; 46(5): 379-399.
41. Kragh-Hansen U. Structure and ligand-binding properties of human serum-albumin. Dan Med Bull 1990; 37 (1): 57-84.
42. Curry S, Mandelkow H, Brick P, et al. Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites. Nat Struct Biol 1998; 5 (9): 827-835.
43. Sugio S, Kashima A, Mochizuki S, Noda M, Kobayashi K. Crystal structure of human serum albumin at 2.5angstrom resolution. Prot Eng 1999; 12 (6): 439-446.
44. Carter DC, Ho JX. Structure of serum-abumin. Adv Prot Chem 1994; 45: 153-203.
45. Paal K, Muller J, Hegedus L. High affinity binding of paclitaxel to human serum albumin. Eur J Biochem 2001; 268 (7): 2187-2191.
46. Purcell M, Neault JF, Tajmir-Riahi HA. Interaction of taxol with human serum albumin. Biochim Biophys Acta 2000; 1478(1): 61-68.
47. Urien S, Barré J, Morin C, Paccaly A, Montay G, Tillement JP. Docetaxel serum protein binding with high affinity to alpha (1)-acid glycoprotein I. Invest New Drugs 1996; 14 (2): 147-151.
48. Liu W. The impact of formulation composition on the stability of freeze dried proteins. Doctoral Dissertation: Purdue University 2000.
49. Chaubal MV. Human serum albumin as a pharmaceutical excipient. 2007. Available at: http://www.drugdeliverytech.com
50. Gradishar WJ, Tjulandin S, Davidson N, et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005; 23: 7794-7803.
51. Ibrahim NK, Samuels B, Page R, et al. Multicenter Phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005; 23: 6019-6026.
52. Desai NP, Trieu V, Yao R, et al. Evidence of greater antitumor activity of Cremophor-free nanoparticle albumin-bound (nab) paclitaxel (Abraxane) compared to Taxol: Role of a novel albumin transporter mechanism. 26th Annual San Antonio Breast Cancer Symposium, San Antonio: USA 2003.
53. Gradishar WJ, Tjulandin S, Davidson N, et al. Superior efficacy of nanoparticle albumin-bound paclitaxel (Abraxane, ABI-007) compared with cremophor-based paclitaxel (Taxol) in women with metastatic breast cancer: Results of a phase III trial. J Clin Oncol 2005; 23: 7794-7803.
54. Desai N, Clark M, Taylor C. Clinical investigator's brochure. ABI-007: nanoparticle paclitaxel for injection. Version3. Los Angeles: American BioScience, Inc. revised November 10, 1999.
55. Damascelli B, Cantu G, Mattavelli F, et al. Intraarterial chemotherapy with polyoxyethylated castor oil free paclitaxel, incorporated in albumin nanoparticles (ABI-007). Cancer 2001; 92: 2592-2602.
56. Soon-Shiong, P., Desai, N. P.: US20030068362 (2003).
57. Kloover JS, den Bakker MA, Gelderblom H, van Meerbeeck JP. Fatal outcome of a hypersensitivity reaction to paclitaxel: A critical review of premedication regimens. Br J Cancer 2004; 90: 304-305.
58. Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: The drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 2001; 37: 1590-1598.
59. Waugh WN, Trissel LA, Stella VJ. Stability, compatibility, and plasticizer extraction of taxol (NSC-125973) injection diluted in infusion solutions and stored in various containers. Am J Hosp Pharm 1991; 48: 1520-1524.
60. Sparreboom A, Scripture CD, Trieu V, et al. Comparative preclinical and clinical pharmacokinetics of a Cremophor-free, nanoparticles albumin-bound paclitaxel (ABI-007) and paclitaxel formulated in Cremophor (Taxol). Clin Cancer Res 2005; 11: 4136-4143.
61. Rahman A, Korzekwa KR, Grogan J, Gonzalez FJ, Harris JW. Selective biotransformation of Taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994; 54: 5543-5546.
62. Cresteil T, Monsarrat B, Alvinerie P, et al. Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 1994; 54: 386-392.
63. Harris JW, Rahman A, Kim BR, Guengerich FP, Collins JM. Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res 1994; 54: 4026-4035.
64. Kumar GN, Walle UK, Walle T. Cytochrome P450 3A-mediated human liver microsomal taxol 6 alpha-hydroxylation. J Pharmacol Exp Ther 1994; 268: 1160-1165.
65. Jamis-Dow CA, Klecker RW, Katki AG, Collins JM. Metabolism of Taxol by human and rat liver in vitro: A screen for drug interactions and interspecies differences. Cancer Chemother Pharmacol 1995; 36: 107-114.
66. Ibrahim NK, Desai N, Legha S. Phase I and pharmacokinetic study of ABI-007, a Cremophor free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin Cancer Res 2002; 8: 1038-1044.
67. van Tellingen O, Huizing MT, Panday VR, Schellens JH, Nooijen WJ, Beijnen JH. Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients. Br J Cancer 1999; 81: 330-335.
68. Kearns CM. Pharmacokinetics of taxanes. Pharmacotherapy 1997; 17: 105S-109S.
69. Mross K, Holländer N, Hauns B, Schumacher M, Maier-Lenz H. The pharmacokinetics of a 1-h paclitaxel infusion. Cancer Chemother Pharmacol 2000; 45: 463-470.
70. Gianni L, Kearns CM, Giani A, et al. Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 1995; 13: 180-190.
71. Nyman DW, Campbell KJ, Hersh E, et al. Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticles formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 2005; 23: 7785-7793.
72. Gardner ER, Dahut WL, Scripture CD, et al. Randomized crossover pharmacokinetic study of solvent-based paclitaxel and nab-paclitaxel. Clin Cancer Res 2008; 14(13): 4200-4205.
73. Hawkins MJ, Soon-Shiong P, Desai N. Protein nanoparticles as drug carriers in clinical medicine. Adv Drug Deliv Rev 2008; 60(8): 876-885.
74. Guan Z, Feng F, Li Q, et al. Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC). J Clin Oncol 2007; 25 (18S): 1038.
75. Rizvi NA, Riely GJ, Azzoli CG. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 2008; 26(4): 639-643.
76. Green MR, Manikhas GM, Orlov S, et al. Abraxane, a novel Cremophor-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17: 1263-1268.
77. Tahir SA, Yang G, Ebara S, et al. Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer. Cancer Res 2001; 61: 3882-3885.
78. Jacob K, Webber M, Benayahu D, Kleinman HK. Osteonectin promotes prostate cancer cell migration and invasion: A possible mechanism for metastasis to bone. Cancer Res 1999; 59: 4453-4457.
79. De S, Chen J, Narizhneva NV, et al. Molecular pathway for cancer metastasis to bone. J Biol Chem 2003; 278: 39044-39050.
80. Li L, Yang G, Ebara S, et al. Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells. Cancer Res 2001; 61: 4386-4392.
81. Yang G, Truong LD, Timme TL, et al. Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res 1998; 4: 1873-1880.
82. Bradley DA, Hussain M. Promising novel cytotoxic agents and combinations in metastatic prostate cancer. Cancer J 2008; 14(1): 15-19.
83. Micha JP, Goldstein BH, Birk CL, Rettenmaier MA, Brown JV 3rd. Abraxane in the treatment of ovarian cancer: The absence of hypersensitivity reactions. Gynecol Oncol 2006; 100(2): 437-438.
84. Hersh EM, Day SO, Gonzalez R, et al. Open-label multicenter, phase II trial of ABI-007 in previously treated and previously untreated patients with metastatic malignant melanoma. 41st American Society of Clinical Oncology Annual Meeting, Orlando, USA 2005.
85. Damascelli B, Patelli GL, Lanocita R, et al. A novel intraarterial chemotherapy using paclitaxel in albumin nanoparticles to treat advanced squamous cell carcinoma of the tongue: Preliminary findings. AJR Am J Roentgenol 2003; 181 (1): 253-260.
86. Desai, N.P., Soon-Shiong, P.: WO2008076373A1 (2008).
87. Mavroudis D, Malamos N, Alexopoulos A, et al. Salvage chemotherapy in anthracycline-pretreated metastatic breast cancer patients with docetaxel and gemcitabine: A multicenter phase II trial. Ann Oncol 1999; 10: 211-215.
88. Delfino C, Caccia G, Riva Gonzales L, et al. Gemcitabine/ paclitaxel as first-line treatment of advanced breast cancer. Oncology 2003; 17 (12S): 22-25.
89. Fountzilas G, Christodoulou C, Tsavdaridis D, et al. Paclitaxel and gemcitabine, as first-line chemotherapy, combined with trastuzumab in patients with advanced breast cancer: A phase II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). Cancer Invest 2004; 22: 655-662.
90. Mavroudis D, Malamos N, Polyzos A, et al. Front-line chemotherapy with docetaxel and gemcitabine administered every two weeks in patients with metastatic breast cancer: A multicenter phase II study. Oncology 2004; 67: 250-256.
91. Seidman AD. Gemcitabine and docetaxel in metastatic breast cancer. Oncology 2004; 18(14S): 13-16.
92. Colomer R. Gemcitabine and paclitaxel in metastatic breast cancer: A review. Oncology 2004; 18(14S): 8-12.
93. Albain KS, Nag S, Calderillo-Ruiz G, et al. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer (MBC): First report of overall survival. J Clin Oncol 2004; 22 (14S): 510.
94. Khoo KS, Zaidi M, Srimuninnimit V, et al. Randomized phase II trial of three gemcitabine (GEM)-paclitaxelcombinations in Metastatic Breast Cancer (MBC). J Clin Oncol 2004; 22 (15S): 710.
95. Lee CB, Stinchcombe TE, Socinski MA, et al. Phase I trial of escalating doses of ABI-007 (nanoparticle albumin-bound paclitaxel) and gemcitabine in patients (pts) with thoracic malignancies. J Clin Oncol 2007; 25 (18S): 18094.
96. Stinchcombe TE, Socinski MA, Lee CB, et al. Phase I trial of nanoparticle albumin-bound paclitaxel in combination with gemcitabine in patients with thoracic malignancies. J Thorac Oncol 2008; 3(5): 521-526.
97. Moreno-Aspitia A, Perez EA. North Central Cancer Treatment Group N0531: Phase II trial of weekly albumin-bound paclitaxel (ABI-007; Abraxane) in combination with gemcitabine in patients with metastatic breast cancer. Clin Breast Cancer 2005; 6: 361-364.
98. Roy V, LaPlant BR, Gross GG, Bane CL, Palmieri FM, Perez EA. North Central Cancer Treatment Group, NCCTG phase II trial N0531 of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC). J Clin Oncol 2007; 25 (18S): 1048.
99. Miller KD. E2100: A phase III trial of paclitaxel versus paclitaxel/ bevacizumab for metastatic breast cancer. Clin Breast Cancer 2003; 3(6): 421-422.
100. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-2676.
101. Link JS, Waisman JR, Nguyen B, Jacobs CI. Bevacizumab and albumin-bound paclitaxel treatment in metastatic breast cancer. Clin Breast Cancer 2007; 7(10): 779-783.
102. Desai, N. P., Soon-Shiong, P.: US2008057562 A1 (2008).
103. Belani CP, Barstis J, Perry MC, et al. Multicenter, randomized trial for stage IIIB or IV non-small-cell lung cancer using weekly paclitaxel and carboplatin followed by maintenance weekly paclitaxel or observation. J Clin Oncol 2003; 21(15): 2933-2939.
104. Allerton JP, Hagenstad CT, Webb RT, et al. A phase II evaluation of the combination of paclitaxel protein-bound and carboplatin in the first-line treatment of advanced non-small cell lung cancer. J Clin Oncol 2006; 24(395s): 7127.
105. Stinchcombe TE, Socinski MA, Walko CM, et al. Phase I and pharmacokinetic trial of carboplatin and albumin bound paclitaxel, ABI-007 (Abraxane) on three treatment schedules in patients with solid tumors. Cancer Chemother Pharmacol 2007; 60: 759-766.
106. Huizing MT, Giaccone G, van Warmerdam LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. J Clin Oncol 1997; 15(1): 317-329.
107. Markman M, Elson P, Kulp B, et al. Carboplatin plus paclitaxel combination chemotherapy: Impact of sequence of drug administration on treatment- induced neutropenia. Gynecol Oncol 2003; 91 (1): 118-122.
108. Hawkins MJ, Georgy M, Makhson A, et al. Dose escalation study of nab-paclitaxel followed by carboplatin as first line therapy in advanced Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2006; 24 (397S): 7132.
109. Hawkins MJ, Manikhas G, Makhson A, et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2007; 25 (18S): 7659.
110. Somer BG, Schwartzberg LS, Arena F, Epperson A, Fu D, Fortner BV. Phase II of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX))+capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC). J Clin Oncol 2007; 25 (18S): 1053.
111. Christopher L, Gilberto L, Orlando S, Stefan G. Paclitaxel albumin-bound particles (abraxape™) in combination with bevacizumab with or without gemcitabine: Early experience at the University of Miami/Braman Family Breast Cancer Institute. Biomed Pharmacother 2007; 61: 531-533.
112. Reynolds C, Barrera D, Vu DQ, et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin and bevacizumab in first-line patients with advanced non-squamous Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2007; 25 (18S): 7610.
113. http://abraxisoncology.com/rnd_pipeline.aspx
114. Desai NP, Trieu V, Hawkins M, et al. Improved effectiveness of nab-paclitaxel versus docetaxel in various xenografts as a function of HER2 and SPARC status. 16th Symposium on Molecular Targets and Cancer Therapeutics, Geneva, Switzerland 2004.
115. Desai NP, Trieu V, Yang A, et al. Enhanced efficacy and safety of nanoparticles albumin-bound nab-docetaxel versus Taxotere. 97th American Association of Cancer Research Annual Meeting, Washington, DC, USA 2006.
116. Guertin DA, Sabatini DM. An expanding role for mTOR in cancer. Trends Mol Med 2005; 11: 353-361.
117. Carraway H, Hidalgo M. New targets for therapy in breast cancer: Mammalian target of (mTOR) antagonists. Breast Cancer Res 2004; 6: 219-224.
118. De T, Trieu V, Yim Z, et al. Nanoparticle albumin-bound (nab) rapamycin as an anti-cancer agent. 98th Amecican Association for Cancer Research Annual Meeting, Los Angeles, USA 2007.
119. Neckers L. Hsp90 inhibitors as novel cancer chemotherapeutic agents. Trends Mol Med 2002; 8 (Suppl 4): S55-61.
120. Tao CL, Yu CZ, De T, et al. Preparation of nanoparticle albumin bound 17AAG (nab-17AAG) suitable for intravenous administration. 96th American Association for Cancer Research Annual Meeting, Anaheim, USA 2005.
121. Desai, N.P., Trieu, V.: WO2008027055 (2008)
122. Raspaglio G, Ferlini C, Mozzetti S, et al. Thiocolchicine dimers: A novel class of topoisomerase-1 inhibitors. Biochem Pharmacol 2005; 69: 113-121.
123. Bernacki RJ, Veith J, Pera P, et al. A novel nanoparticle albumin bound thiocolchicine dimer (nab-5404) with dual mechanisms of action on tubulin and topoisomerase-1: Evaluation of in vitro and in vivo activity. 96th American Association of Cancer Research Annual Meeting, Anaheim, USA 2005.
124. Desai NP, De T, Trieu V, Hawkins MJ, Soon-Shiong P. Nanoparticle albumin bound (nab) dimeric thiocolchicines nab-5404, nab-5800, and nab-5801: A comparative evaluation of antitumor activity vs Abraxane and Irinotecan. 96th American Association of Cancer Research Annual Meeting, Anaheim, USA 2005.
125. Trieu V, De T, Labao E, et al. Anti-angiogenic and antitumor activity of nanoparticle albumin bound (nab) thiocolchicine dimer (IDN5404) with a novel dual mechanism of action on tubulin and topoisomerase-1. 97th American Association of Cancer Research Annual Meeting. Washington, DC, USA 2006.